TransMedics Group, Inc. (TMDX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 26 | 30 | 93 | 242 | 442 | 605 | 668 | 743 |
| Operating profit | $m | 109 | 82 | ||||||
| Net profit | $m | -29 | -44 | -36 | -25 | 35 | 190 | 152 | 58 |
| EPS reported | $ | 4.87 | 3.86 | ||||||
| Operating cashflow per share | $ | 5.67 | 4.22 | ||||||
| Capex per share | $ | 1.74 | 1.93 | ||||||
| FCF per share | $ | 3.93 | 2.29 | ||||||
| Free cash flow | $m | 134 | 79 | ||||||
| Net debt | $m | -19 | 41 | ||||||
| Book value equity | $m | 473 | 518 | ||||||
| Book value per share | $ | 11.67 | 12.73 | ||||||
| Number of shares | m | 40.54 | 40.71 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 24.98 | 22.10 | ||||||
| P/B LTM | x | 8.74 | 7.98 | ||||||
| P/S LTM | x | 6.83 | 6.19 | ||||||
| P/FCF LTM | x | 30.96 | 52.32 | ||||||
| EV/EBITDA LTM | x | 27.72 | 34.31 | ||||||
| EV/Sales LTM | x | 6.80 | 5.11 | ||||||
| Earnings Yield LTM | % | +4.00% | +4.52% | ||||||
| FCF Yield | % | +3.23% | +1.91% | ||||||
| Quality | |||||||||
| ROE | % | +40.22% | +32.97% | ||||||
| ROIC | % | +10.94% | +5.87% | ||||||
| Operating margin | % | +17.93% | +12.21% | ||||||
| Gross margin | % | +59.92% | +58.69% | ||||||
| FCF/Sales | % | +22.06% | +11.82% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +382.18% | +282.18% | ||||||
| Sales Growth YoY | % | +37.13% | +51.39% | ||||||
| Net Income Growth YoY | % | +436.58% | +327.75% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +189.59% | +117.64% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.28 | 0.09 | ||||||
| Net Debt/EBITDA | x | -0.13 | 3.29 | ||||||
| EBIT/Net interest | x | 7.88 | 3.84 | ||||||
| Net debt/market cap | % | +11.36% | +17.15% | ||||||
| Net debt/Equity | x | -0.04 | 0.08 | ||||||
| Gross debt/equity | x | 0.99 | 1.67 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free